Page last updated: 2024-11-04
rofecoxib and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
rofecoxib has been researched along with Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted in 1 studies
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Sofosbuvir (SOF) and daclatasvir (DCS) are novel, recently developed direct acting antiviral agents characterized by potent anti-hepatitis C virus action." | 7.88 | Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits. ( Abo-Zeid, MN; Atia, NN; El-Gizawy, SM; El-Shaboury, SR, 2018) |
| "Sofosbuvir (SOF) and daclatasvir (DCS) are novel, recently developed direct acting antiviral agents characterized by potent anti-hepatitis C virus action." | 3.88 | Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits. ( Abo-Zeid, MN; Atia, NN; El-Gizawy, SM; El-Shaboury, SR, 2018) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Atia, NN | 1 |
| El-Shaboury, SR | 1 |
| El-Gizawy, SM | 1 |
| Abo-Zeid, MN | 1 |
Other Studies
1 other study available for rofecoxib and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted